Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation.

Mantovani, Giovanni; Macciò, Antonio; Massa, Elena; Mulas, Carlo; Mudu, Maria Caterina; Massidda, Stefania; Massa, D.; Murgia, V.; Ferreli, Luca; Succu, G; Astara, Giorgio; Proto, E; Töre, G; Mura, Marie; Maxia, G

doi:10.3892/ijo.16.6.1227

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In treating patients with advanced head and neck cancer, there has been a recent trend away from surgery towards chemotherapy and/or radiotherapy thereby improving tumour response rates and disease control whilst attempting to achieve organ preservation. [6][7][8][9][10][11][12] Ahmed et al 6 used concomitant chemoradiotherapy and surgical salvage for N3 nodal disease. Intra-arterial cisplatin and radiotherapy was given with surgical salvage for patients with N3 nodal disease.…”

Section: Discussionmentioning

confidence: 99%

Outcomes in Squamous Cell Carcinoma with Advanced Neck Disease

Keir

Whiteside

Winter

et al. 2007

annals

View full text Add to dashboard Cite

INTRODUCTION Treatment of advanced neck disease (N2c/N3) in head and neck squamous cell carcinoma is contentious. The aim of this study was to review the survival outcome following surgical excision of neck disease and the complications of this surgery. PATIENTS AND METHODS A retrospective review of the case notes of 39 patients treated at the Oxford Radcliffe Infirmary Head and Neck Unit with squamous cell carcinoma and advanced neck metastases confirmed as either pN2c or pN3 on histological examination was performed. Patients were treated with surgery and, in some cases, with adjunctive postoperative radiotherapy at the centre between August 1996 and November 2004. The study sought to establish the demographics, UICC staging/pathology, method of treatment, complications, recurrence and survival. Kaplan-Meier curves were used for statistical analysis of survival. Comparisons were then made between the cohort and historical control groups. RESULTS All patients were UICC stage IV disease. The 2- and 5-year overall survival in patients with resectable disease was 63% and 52%, respectively. DISCUSSION Patients with advanced neck disease have traditionally been thought to have terrible prognosis and, therefore, treatment is controversial. In treating advanced head and neck cancer, there has been a recent trend away from surgery towards chemotherapy and/or radiotherapy. CONCLUSIONS Comparing this study group to historical controls that include chemotherapy and/or radiotherapy, the outcomes appear favourable. The use of a combination of radiotherapy and surgery is advocated; it is suggested that advanced neck disease can have an acceptable prognosis and morbidity and that local disease control may be achieved.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes in Squamous Cell Carcinoma with Advanced Neck Disease

Keir

Whiteside

Winter

et al. 2007

annals

View full text Add to dashboard Cite

show abstract

“…Cisplatin is a potent inductor of apoptosis in different cell types and is one of the most effective and widely used chemotherapeutic agents for the treatment of human cancers, including head and neck cancer 1. Apoptosis induced by cisplatin is generally considered to be the result of its ability to damage DNA2, 3, 4, 5; however, many studies have suggested that cisplatin stimulates cells to produce reactive oxygen species (ROS).…”

Section: Introductionmentioning

confidence: 99%

Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1

Folmer¹,

Mark²,

Ho-Mok³

et al. 2009

Hepatology

View full text Add to dashboard Cite

Mutations in ATP8B1 cause progressive familial intrahepatic cholestasis type 1 (PFIC1) and benign recurrent intrahepatic cholestasis type 1 (BRIC1), forming a spectrum of cholestatic disease. Whereas PFIC1 is a progressive, endstage liver disease, BRIC1 patients suffer from episodic periods of cholestasis that resolve spontaneously. At present it is not clear how the type and location of the mutations relate to the clinical manifestations of PFIC1 and BRIC1. ATP8B1 localizes to the canalicular membrane of hepatocytes where it mediates the inward translocation of phosphatidylserine. ATP8B1 interacts with CDC50A, which is required for endoplasmic reticulum exit and plasma membrane localization. In this study we analyzed a panel of missense mutations causing PFIC1 (G308V, D554N, G1040R) or BRIC1 (D70N, I661T). In addition, we included two mutations that have been associated with intrahepatic cholestasis of pregnancy (ICP) (D70N, R867C). We examined the effect of these mutations on protein stability and interaction with CDC50A in Chinese hamster ovary cells, and studied the subcellular localization in WIF-B9 cells. Protein stability was reduced for three out of six mutations studied. Two out of three PFIC1 mutant proteins did not interact with CDC50A, whereas BRIC1/ICP mutants displayed reduced interaction. Importantly, none of the PFIC1 mutants were detectable in the canalicular membrane of WIF-B9 cells, whereas all BRIC1/ICP mutants displayed the same cellular staining pattern as wild-type ATP8B1. Our data indicate that PFIC1 mutations lead to the complete absence of canalicular expression, whereas in BRIC1/ICP residual protein is expressed in the canalicular membrane. Conclusion: These data provide an explanation for the difference in severity between the phenotypes of PFIC1 and BRIC1. (HEPATOLOGY 2009;50: 1597-1605

show abstract

“…Cisplatin (cis‐diamminedichloroplatinum) is a DNA‐damaging agent that has been used in head and neck cancer, both alone and in combination with other chemotherapeutic agents or radiation therapy 38. Development of cisplatin resistance is a major obstacle in clinical treatment 39.…”

mentioning

confidence: 99%